Skip to main content Accessibility help
×
Home

Position Statement on the Use of Medical Cannabis for the Treatment of Epilepsy in Canada: By the Canadian League Against Epilepsy Medical Therapeutics Committee, Invited Experts and Collaborators

  • Juan Pablo Appendino (a1), Cyrus Boelman (a1), Paula M. Brna (a1), Jorge G. Burneo (a1), Curtis S. Claassen (a1), Mary B. Connolly (a1), Michael V. T. De Guzman (a1), Paolo Federico (a1), Deirdre Floyd (a1), Richard James Huntsman (a1), Manouchehr Javidan (a1), Nathalie Jette (a1), Laura L Jurasek (a1), Mark R. Keezer (a1), Jonathan C. Lau (a1), Bláthnaid McCoy (a1), Richard S McLachlan (a1), Marcus C. Ng (a1), Dang Khoa Nguyen (a1), Aylin Y Reid (a1), Jong M. Rho (a1), O. Carter Snead (a1), José F. Téllez-Zenteno (a1), Laura Wang (a1) and Maria Martha Zak (a1)...

Abstract:

In Canada, recreational use of cannabis was legalized in October 2018. This policy change along with recent publications evaluating the efficacy of cannabis for the medical treatment of epilepsy and media awareness about its use have increased the public interest about this agent. The Canadian League Against Epilepsy Medical Therapeutics Committee, along with a multidisciplinary group of experts and Canadian Epilepsy Alliance representatives, has developed a position statement about the use of medical cannabis for epilepsy. This article addresses the current Canadian legal framework, recent publications about its efficacy and safety profile, and our understanding of the clinical issues that should be considered when contemplating cannabis use for medical purposes.

  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Position Statement on the Use of Medical Cannabis for the Treatment of Epilepsy in Canada
      Available formats
      ×

      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      Position Statement on the Use of Medical Cannabis for the Treatment of Epilepsy in Canada
      Available formats
      ×

      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      Position Statement on the Use of Medical Cannabis for the Treatment of Epilepsy in Canada
      Available formats
      ×

Copyright

Corresponding author

Correspondence to: Juan Pablo Appendino, Cumming School of Medicine, Alberta Children’s Hospital, University of Calgary, 28 Oki Drive NW, Calgary, AB T3B 6A8, Canada. Email: jp.appendino@ahs.ca

References

Hide All
1.Husni, AS, McCurdy, CR, Radwan, MM, et al. Evaluation of phytocannabinoids from high-potency Cannabis sativa using in vitro bioassays to determine structure–activity relationships for cannabinoid receptor 1 and cannabinoid receptor 2. J Med Chem Res. 2014;23(9):4295–300.
2.Friedman, D, Devinsky, O. Cannabinoids in the treatment of epilepsy. New Eng J Med. 2015;373:1048–58.
3.O‘Connell, BK, Gloss, D, Devinsky, O. Cannabinoids in treatment-resistant epilepsy: a review. Epilepsy Behav. 2017;70(Pt B):341–48.
4.Szaflarski, JP, Bebin, EM, Comi, AM, et al. CBD EAP study group. Long-term safety and treatment effects of cannabidiol in children and adults with treatment-resistant epilepsies: Expanded access program results. Epilepsia. 2018;59(8):1540–48. doi: 10.1111/epi.14477. Epub July 12, 2018.
5.Devinsky, O, Verducci, C, Thiele, EA, et al. Open-label use of highly purified CBD (Epidiolex®) in patients with CDKL5 deficiency disorder and Aicardi, Dup15q, and Doose syndromes. Epilepsy Behav. 2018;86:131–37. doi: 10.1016/j.yebeh.2018.05.013. Epub July 11, 2018.
6.McCoy, B, Wang, L, Zak, M, et al. A prospective open-label trial of a CBD/THC cannabis oil in Dravet syndrome. Ann Clin Transl Neurol. 2018;5(9):10771088. doi: 10.1002/acn3.621. eCollection September 2018.
7.Devinsky, O, Patel, AD, Thiele, EA, et al. GWPCARE1 Part A Study Group. Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome. Neurology. 2018;90(14):e1204e1211. doi: 10.1212/WNL.0000000000005254. Epub March 14, 2018.
8.Devinsky, O, Cross, JH, Laux, L, et al. Cannabidiol in Dravet Syndrome Study Group. Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome. N Engl J Med. 2017;376(21):2011–20. doi: 10.1056/NEJMoa1611618.
9.Devinsky, O, Patel, AD, Cross, JH, et al. GWPCARE3 Study Group. Effect of cannabidiol on drop seizures in the Lennox-Gastaut syndrome. N Engl J Med. 2018;378(20):1888–97. doi: 10.1056/NEJMoa1714631.
10.Thiele, EA, Marsh, ED, French, JA, et al. GWPCARE Study Group. Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2018;391(10125):1085–96. doi: 10.1016/S0140-6736(18)30136-3. Epub January 26, 2018.
11.McLachlan, RS. Marijuana: a time-honored but untested treatment for epilepsy. Can J Neurol Sci. 2015;42(2):88–91. doi: 10.1017/cjn.2015.11. Epub February 26, 2015.
12.Rieder, MJ. Canadian Paediatric Society, Drug Therapy and Hazardous Substances Committee. Is the medical use of cannabis a therapeutic option for children? Paediatr Child Health. 2016; 21(1):3134.
13.Consolidation of Cannabis Regulations. SOR/2018-Last amended on January 15; 2019. Available at: https://laws-lois.justice.gc.ca/PDF/SOR-2018-144.pdf; accessed May 19, 2019.
14.Gaston, TE, Friedman, D. Pharmacology of cannabinoids in epilepsy. Epilepsy Behav. 2017;70(Pt B):313–8.
15.Reddy, DS, Golub, VM. The pharmacological basis of cannabis therapy for epilepsy. J Pharmacol Exp Ther. 2016;357(1):4555.
16.Dow-Edwards, D, Silva, L. Endocannabinoids in brain plasticity: cortical maturation, HPA axis function and behavior. Brain Res. 2017;1654(Pt B):157–64.
17.Gloss, D, Vickrey, B. Cannabinoids for epilepsy. Cochrane Database Syst Rev. 2014;5(3):CD009270.
18.Koppel, BS, Brust, JCM, Fife, T, et al. Systematic review: efficacy and safety of medical marijuana in selected neurologic disorders: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology 2014;82(17):1556–63.
19.Elliott, J, DeJean, D, Clifford, T, et al. Cannabis-based products for pediatric epilepsy: a systematic review. Epilepsia. 2019;60(1):619.
20.Pavlovic, R, Nenna, G, Calvi, L, et al. Quality traits of “Cannabidiol Oils”: cannabinoids content, terpene fingerprint and oxidation stability of European commercially available preparations. Molecules. 2018;23(5). pii: E1230.
21.Devinsky, O, Marsh, E, Friedman, D, et al. Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial. Lancet Neurol. 2016;15(3):270–78. Erratum in: Lancet Neurol. 2016 Apr;15(4):352.
22.Volkow, ND, Swanson, JM, Evins, AE, et al. Effects of cannabis use on human behavior, including cognition, motivation, and psychosis: a review. JAMA Psychiatry. 2016;73(3):292–7.
23.Williamson, EM, Evans, FJ. Cannabinoids in clinical practice. Drugs. 2000;60(6):1303–14.
24.Calvigioni, D, Hurd, YL, Harkany, T, Keimpema, E. Neuronal substrates and functional consequences of prenatal cannabis exposure. Eur Child Adolesc Psychiatry. 2014;23(10):931–1.
25.Petrangelo, A, Czuzoj-Shulman, N, Balayla, J, Abenhaim, HA. Cannabis abuse or dependence during pregnancy: a population-based cohort study on 12 million births. J Obstet Gynaecol Can. 2019;41(5):623−30.
26.Leung, MCK, Silva, MH, Palumbo, AJ, Lohstroh, PN, Koshlukova, SE, DuTeaux, SB. Adverse outcome pathway of developmental neurotoxicity resulting from prenatal exposures to cannabis contaminated with organophosphate pesticide residues. Reprod Toxicol. 2019;85:1218.
27.Gaston, TE, Bebin, EM, Cutter, GR, et al. Interactions between cannabidiol and commonly used antiepileptic drugs. Epilepsia. 2017;58(9):1586–92. doi: 10.1111/epi.13852. Epub August 6, 2017.
28.Burnham, EL, Eakin, MN, Pakhale, S. Ethics of health research supported by for-profit cannabis companies: what have we learned from Big Tobacco? Ann Am Thorac Soc. 2019;16(3):396–7.

Keywords

Related content

Powered by UNSILO

Position Statement on the Use of Medical Cannabis for the Treatment of Epilepsy in Canada: By the Canadian League Against Epilepsy Medical Therapeutics Committee, Invited Experts and Collaborators

  • Juan Pablo Appendino (a1), Cyrus Boelman (a1), Paula M. Brna (a1), Jorge G. Burneo (a1), Curtis S. Claassen (a1), Mary B. Connolly (a1), Michael V. T. De Guzman (a1), Paolo Federico (a1), Deirdre Floyd (a1), Richard James Huntsman (a1), Manouchehr Javidan (a1), Nathalie Jette (a1), Laura L Jurasek (a1), Mark R. Keezer (a1), Jonathan C. Lau (a1), Bláthnaid McCoy (a1), Richard S McLachlan (a1), Marcus C. Ng (a1), Dang Khoa Nguyen (a1), Aylin Y Reid (a1), Jong M. Rho (a1), O. Carter Snead (a1), José F. Téllez-Zenteno (a1), Laura Wang (a1) and Maria Martha Zak (a1)...

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed.